ESPERION

Unlocking Value in a High-Need, High-Impact Disease

A patient-driven strategy, differentiated science and experienced leadership combine to drive long-term value

Patient-Focused Strategy

- Targeting a disease with **no approved therapies** to slow progression
- Committed to delivering significant therapeutic impact in an area of **profound unmet need**
- **Strengthened ties** with **PSC patients** by working closely with PSC-focused advocacy groups
- Potential for **rare and orphan drug designation,** proving opportunities to deliver the therapy to patients sooner

Scientific Edge

- **Deep expertise** in ACLY biology and inhibition
- **Novel and differentiated** mechanism of action
- Targeting **multiple mechanisms of PSC progression:** injury, inflammation and fibrosis
- **Strong partnerships** and **research collaborations** enhancing execution

Experienced Leadership

- **First to discover,** develop, and globally commercialize ACLYi therapy
- Decades of **end-to-end drug discovery, development, and commercialization experience**, including in orphan and rare diseases
- **Fully built organization** with all core functions in place

Primary Sclerosing Cholangitis (PSC): A Rare and Chronic Liver Disease

- **Progressive inflammatory and fibrotic disease that injures bile ducts**
- **No approved therapy with proven efficacy to cure or halt PSC progression**
- **Peak incidence occurs between ages 25-45, during most productive years of life**
- **Average time from diagnosis to liver transplant or death is 10-20 years**



High Unmet Need Driving Significant Market Opportunity with Potential Orphan Drug Designation & Fast Track Approval

~46,000

Patients diagnosed with PSC across **United States**

~30,000

Patients diagnosed with PSC across **Europe**

>$1 Billion Annually

Estimated Market Opportunity

Esperion's oral next generation ACLY inhibitor has the potential to be the only agent to directly inhibit all 3 mechanisms of PSC disease progression



Innovative ACLY Inhibitor Discovery Program Designed for PSC

- Applied **advanced discovery** approaches and **technology** to design the next generation of **differentiated ACLY inhibitors**
- Leveraged **multi-omic data and human genetics** to identify novel ACLY pathways relevant to **liver disease**
- Developed a **custom screening cascade** to optimize compound activity for **PSC-specific mechanisms**
- **De-risked, highly potent** and **selective** allosteric ACLY inhibitor **leads and backups selected**
- Pharmacokinetic properties enable **convenient once-daily oral dosing**
- **Compelling preclinical evidence** confirm reductions in liver injury, inflammation and fibrosis in multiple PSC-relevant models, **reinforcing therapeutic potential**

We're Off to a Strong Start